(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.54%) $78.90
(0.14%) $2.20
(0.13%) $2 334.20
(0.26%) $27.69
(0.22%) $967.00
(0.02%) $0.928
(0.05%) $10.83
(0.02%) $0.796
(-0.01%) $91.34
Live Chart Being Loaded With Signals
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms...
Stats | |
---|---|
今日成交量 | 937 047 |
平均成交量 | 1.04M |
市值 | 6.63B |
EPS | INR0 ( 2024-02-12 ) |
下一个收益日期 | ( INR0 ) 2024-05-13 |
Last Dividend | INR1.000 ( 2011-09-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 15.27 |
ATR14 | INR0.226 (0.20%) |
音量 相关性
Ind-Swift Laboratories 相关性
10 最正相关 | |
---|---|
PVP.NS | 0.827 |
ICICIPHARM.NS | 0.813 |
KIMS.NS | 0.811 |
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Ind-Swift Laboratories 相关性 - 货币/商品
Ind-Swift Laboratories 财务报表
Annual | 2022 |
营收: | INR12.07B |
毛利润: | INR5.52B (45.70 %) |
EPS: | INR8.06 |
FY | 2022 |
营收: | INR12.07B |
毛利润: | INR5.52B (45.70 %) |
EPS: | INR8.06 |
FY | 2022 |
营收: | INR10.39B |
毛利润: | INR4.28B (41.20 %) |
EPS: | INR-0.360 |
FY | 2021 |
营收: | INR8.91B |
毛利润: | INR3.61B (40.51 %) |
EPS: | INR-0.530 |
Financial Reports:
No articles found.
Ind-Swift Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR1.000 | 2004-09-23 |
Last Dividend | INR1.000 | 2011-09-20 |
Next Dividend | INR0 | N/A |
Payout Date | 2011-10-26 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | INR9.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.21 | -- |
Div. Sustainability Score | 1.760 | |
Div.Growth Potential Score | 2.47 | |
Div. Directional Score | 2.12 | -- |
Year | Amount | Yield |
---|---|---|
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TIPSINDLTD.NS | Dividend Knight | 2023-08-03 | Annually | 17 | 0.03% | |
PEL.NS | Dividend Junior | 2023-06-16 | Annually | 29 | 1.59% | |
JAICORPLTD.NS | Dividend Junior | 2023-09-04 | Annually | 17 | 0.27% | |
DBCORP.NS | Dividend Knight | 2023-08-01 | Semi-Annually | 15 | 3.47% | |
SIGIND.NS | Ex Dividend Junior | 2023-09-22 | Annually | 11 | 0.62% | |
MAZDA.NS | Dividend Junior | 2023-09-07 | Annually | 8 | 1.43% | |
GUFICBIO.NS | Dividend Junior | 2023-09-21 | Annually | 20 | 0.04% | |
BASF.NS | Dividend Junior | 2023-07-20 | Annually | 23 | 0.18% | |
PRECWIRE.NS | Dividend Junior | 2023-08-28 | Semi-Annually | 23 | 1.28% | |
KALYANIFRG.NS | Dividend Junior | 2023-09-13 | Annually | 17 | 0.81% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0362 | 1.500 | 9.28 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0612 | 1.500 | -0.431 | -0.647 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 2.56 | 1.000 | -0.163 | -0.163 | [3 - 30] |
operatingCashFlowPerShareTTM | 16.90 | 2.00 | 4.37 | 8.74 | [0 - 30] |
freeCashFlowPerShareTTM | 16.90 | 2.00 | 1.552 | 3.10 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.476 | 1.000 | 5.40 | 5.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.181 | 1.000 | 8.37 | 8.37 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.760 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 15.47 | 1.000 | 8.54 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0612 | 2.50 | -0.277 | -0.647 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 16.90 | 2.00 | 4.37 | 3.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 16.90 | 2.00 | 4.37 | 8.74 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.482 | 1.500 | -0.118 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0838 | 1.000 | -0.406 | 0 | [0.1 - 0.5] |
Total Score | 2.47 |
Ind-Swift Laboratories
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。